R R

What Is Saphnelo?

Saphnelo is a prescription biologic medication containing anifrolumab-fnia, a monoclonal antibody that blocks the type I interferon receptor. It is approved for adults with moderate to severe systemic lupus erythematosus who are receiving standard treatment. Systemic lupus erythematosus is an autoimmune disease that can cause inflammation affecting the skin, joints, blood cells, and internal organs. Saphnelo reduces specific immune signals involved in lupus activity. It is available for intravenous infusion and subcutaneous injection, with different dosing schedules. Saphnelo does not cure lupus and is not recommended for patients with severe active lupus nephritis or severe active central nervous system lupus.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Saphnelo?

Saphnelo is a prescription biologic medication containing anifrolumab-fnia, a monoclonal antibody that blocks the type I interferon receptor. It is approved for adults with moderate to severe systemic lupus erythematosus who are receiving standard treatment. Systemic lupus erythematosus is an autoimmune disease that can cause inflammation affecting the skin, joints, blood cells, and internal organs. Saphnelo reduces specific immune signals involved in lupus activity. It is available for intravenous infusion and subcutaneous injection, with different dosing schedules. Saphnelo does not cure lupus and is not recommended for patients with severe active lupus nephritis or severe active central nervous system lupus.

read more about saphnelo ...

Copy this HTML:

Copy HTML Copied!

How Does Saphnelo Work?

Saphnelo binds to subunit 1 of the type I interferon receptor, known as IFNAR1. Type I interferons are signaling proteins involved in immune responses, and excessive activity in this pathway contributes to inflammation in many patients with systemic lupus erythematosus. By blocking the receptor, anifrolumab reduces interferon-related signaling and the expression of inflammatory genes. This can help decrease lupus disease activity and improve certain symptoms when added to standard treatment. Saphnelo does not eliminate the underlying autoimmune disorder. Interferon signaling also participates in defenses against infections, so blocking the pathway can increase susceptibility to certain infections.

What Condition Does Saphnelo Treat?

Saphnelo is approved for adults with moderate to severe systemic lupus erythematosus who are already receiving standard therapy. Lupus can cause joint pain, skin rashes, fatigue, inflammation, and periods of increased disease activity called flares. Saphnelo is used when a clinician determines that additional control of systemic lupus activity is appropriate. Its effectiveness has not been evaluated adequately in severe active lupus nephritis or severe active central nervous system lupus, and its use is not recommended in those situations. A rheumatologist reviews disease manifestations, infection history, vaccination status, other immune-suppressing treatments, and previous medication responses before prescribing it.

How Is Saphnelo Administered?

Saphnelo may be administered as a 300 mg intravenous infusion over 30 minutes every four weeks or as a 120 mg subcutaneous injection once weekly. Intravenous doses are prepared and administered by healthcare professionals. The subcutaneous formulation is available in a prefilled syringe or autoinjector, and patients or caregivers may administer it after appropriate training and assessment. These formulations have different dosing schedules and should not be interchanged without medical direction. Patients should be assessed for active infections before treatment and review vaccination needs with their clinician. Live or live-attenuated vaccines should be avoided during Saphnelo treatment.

What Are the Side Effects and Warnings of Saphnelo?

Common adverse effects include upper respiratory infections, bronchitis, infusion-related reactions, cough, and shingles caused by herpes zoster. Serious infections, including potentially fatal infections, can occur during treatment. Saphnelo can also cause severe hypersensitivity reactions, including anaphylaxis and angioedema. Clinicians consider malignancy risk and the patient's history of persistent or recurrent infections before treatment. Saphnelo should generally not be started during an active infection, and new serious infections may require treatment interruption. Patients should report persistent fever, painful blistering rashes, breathing difficulties, or facial swelling promptly. Vaccination history and infection risk should be reviewed throughout therapy.

Common Questions About Saphnelo

Is Saphnelo the same as anifrolumab?

Yes. Saphnelo contains anifrolumab-fnia, a monoclonal antibody that blocks type I interferon receptor signaling.

Can Saphnelo treat lupus nephritis?

Saphnelo is approved for moderate to severe systemic lupus erythematosus, but its use is not recommended for severe active lupus nephritis because effectiveness in that population has not been established.

How often is Saphnelo administered?

Intravenous Saphnelo is given every four weeks. The subcutaneous formulation is injected once weekly.

Does Saphnelo increase infection risk?

Yes. Saphnelo can increase susceptibility to infections, including shingles and serious respiratory infections. Patients should report signs of infection promptly.

References

Anifrolumab-fnia Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621046.html. Date Accessed November 6, 2026.

DailyMed - SAPHNELO (anifrolumab-fnia) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6203302-2128-41a7-b0b4-0e6c0704d4dc. Date Accessed November 6, 2026.

SAPHNELO Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761123s012lbl.pdf. Date Accessed November 6, 2026.

Saphnelo. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo. Date Accessed November 6, 2026.

Trial of Anifrolumab in Active Systemic Lupus Erythematosus. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1912196. Date Accessed November 6, 2026.